Susceptibility Testing of Fungi to Antifungal Drugs
Open accessThe DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Abstract
Susceptibility testing of fungi against antifungal drugs commonly used for therapy is a key component of the care of patients with invasive fungal infections. Antifungal susceptibility testing (AFST) has progressed in recent decades to finally become standardized and available as both Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) reference methods and in commercial manual/automated phenotypic methods. In clinical practice, the Sensititre YeastOne and Etest methods are widely used for AFST, particularly for sterile site isolates of Candida. Nevertheless, AFST is moving toward new phenotypic methods, such as matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS), that are capable of providing rapid, and potentially more actionable, results for the treating clinician. Our objective is to summarize updated data on phenotypic methods for AFST of Candida and Aspergillus species and to assess their significance in view of opposing, but emerging, molecular genotypic methods.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Potential treatment of invasive C. glabrata infection based on mass spectrometry– antifungal susceptibility testing (MS-AFST) results. In a clinical context of prior echinocandin exposure, results of susceptibility or resistance to anidulafungin and/or fluconazole within 3 h or, in cases of isolates with FKS2 HS1 mutations, 6–12 h after testing may guide the appropriate administration of antifungal therapy [69].](https://figures.cochat.ai/paper-figures/fd76e521811c4664bee8bad9f57a9b83/susceptibility-testing-of-fungi-to-antifungal-drugs-figure-1.jpg)
![Figure 2 Potential screening of azole-resistant A. fumigatus isolates. Shown is a stepwise workflow that eliminates false-positive results (indicated by a red X) and can be helpful to build up local epidemiological data on the prevalence and phylogenetic linkage of resistant isolates. In this figure, true positives are derived from the growth of isolates on selective agar plates containing drug concentrations that range from 0.5 μg/mL for posaconazole (PSZ) to 1 to 4 μg/mL for itraconazole (ITZ) or voriconazole (VRZ). Then, isolates are identified at the species level by multilocus DNA sequencing [46] (got permission to use).](https://figures.cochat.ai/paper-figures/d240c50e04e54fbdb42cad175fb309aa/susceptibility-testing-of-fungi-to-antifungal-drugs-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Our findings also suggest an opportunity for increased use of AFST because AFST results can be an important adjunct in clinical decision-making [30].”
From Treatment practices for adults with candidemia at 9 active surveillance sites—United States, 2017–2018. (2021) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 2×
“As for Candida and Aspergillus, the i fection-related mortality rates are still unacceptably hig , despite recent advances in prophylaxis, e rly diagnosis, and treatment of fungal diseases [1].”
BackgroundPatterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Seng, P., Drancourt, M., Gouriet, F., La Scola, B., Fournier, P., Rolain, J. M., & Raoult, D. (2009) · Clinical Infectious Diseases · doi:10.1086/600885 · Cited by 1,983 · cited 1×
“However, this has occurred quickly for bacteria [58] but not so quickly for fungi [59].”
BackgroundLockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662
Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556
Self-citationWorldwide emergence of resistance to antifungal drugs challenges human health and food security
Fisher, M. C., Hawkins, N. J., Sanglard, D., & Gurr, S. J. (2018) · Science · doi:10.1126/science.aap7999 · Cited by 1,555 · cited 1×
“Invasive fungal infections, especially those caused by the species Candida and Aspergillus, continue to rise in frequency [1] and, alarmingly, are associated with antifungal resistance [2], which makes the management of patients with such infections particularly challenging [3,4].”
BackgroundPappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ1194 · Cited by 1,298 · cited 3×
“glabrata against azoles and echinocandins [5].”
BackgroundCornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217 · cited 1×
“Echinocandins represent first-line treatment of invasive Candida infections [5,31,32].”
BackgroundThe global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Clark, A. E., Kaleta, E. J., Arora, A., & Wolk, D. M. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00072-12 · Cited by 941 · cited 1×
“In many European clinical microbiology laboratories such as ours, the advent of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) has drastically altered the routine diagnostic workflow [55,56].”
BackgroundAntifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
Pfaller, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.001 · Cited by 903 · cited 1×
“, determining which antifungal agents are likely to be clinically inactive [83].”
BackgroundEmergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance Mechanism
Snelders, E., van der Lee, H. A. L., Kuijpers, J., Rijs, A. J. M. M., Varga, J., Samson, R. A., Mellado, E., Donders, A. R. T., Melchers, W. J. G., & Verweij, P. E. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050219 · Cited by 727 · cited 3×
“The most frequently observed mutation is TR34/L98H, which consists of a 34 bp tandem repeat (TR34) in the gene promoter region combined with the substitution of leucine 98 for histidine (L98H) [47].”
BackgroundMultidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment
Arendrup, M. C., & Patterson, T. F. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix131 · Cited by 707
Mechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647 · cited 1×
“Although acquired azole resistance in Candida species is multifaceted [70], the induction of drug efflux encoded by CDR genes and regulation of their expression by mutations in the transcription factor CgPdr1 (encoded by the CgPDR1 gene) represent the most clinically relevant”
BackgroundVerweij, P. E., Chowdhary, A., Melchers, W. J. G., & Meis, J. F. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ885 · Cited by 561 · cited 2×
“Consistent with the role of triazoles in the treatment and/or prophylaxis of invasive aspergillosis [43], CLSI-based ECVs for itraconazole, posaconazole, voriconazole, and, lately, isavuconazole were established for Aspergillus species (A.”
Pfaller, M. A., & Diekema, D. J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00937-12 · Cited by 484 · cited 2×
“) between the two [16], CLSI and EUCAST have been proven to yield, upon completion of testing, comparable MIC data for all classes of antifungal agents [19,20].”
Arendrup, M. C., Cuenca-Estrella, M., Lass-Flörl, C., & Hope, W. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03880.x · Cited by 451 · cited 2×
“In particular, the EUCAST method uses a higher percentage of glucose (2%) in the test medium to facilitate increased fungal growth [14,15], which may be particularly advised when testing molds.”
Echinocandin resistance in Candida.
Perlin, D. S. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ791 · Cited by 374
Has antifungal susceptibility testing come of age
Rex, J. H., & Pfaller, M. A. (2002) · Clinical Infectious Diseases · doi:10.1086/342384 · Cited by 361 · cited 2×
“In a viewpoint article published ~15 years ago, Rex and Pfaller [11], while discussing the accuracy of the “90–60 rule” by which AFST can predict the outcome of treatment, said that AFST “has indeed come of age as a useful clinical tool.””
BackgroundMolecular and Nonmolecular Diagnostic Methods for Invasive Fungal Infections
Arvanitis, M., Anagnostou, T., Fuchs, B. B., Caliendo, A. M., & Mylonakis, E. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00091-13 · Cited by 353 · cited 2×
“To date, MALDI-TOF MS analysis is suited for microbial isolates cultured from primary samples [60] or positive blood cultures [61], significantly reducing the turnaround time compared to biochemical [62] or nucleic acid–based techniques, such as DNA sequencing [63].”
BackgroundMethodUllmann, A. J., Akova, M., Herbrecht, R., Viscoli, C., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Calandra, T., Castagnola, E., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12041 · Cited by 334 · cited 1×
“Echinocandins represent first-line treatment of invasive Candida infections [5,31,32].”
Verweij, P. E., Ananda-Rajah, M., Andes, D., Arendrup, M. C., Brüggemann, R. J., Chowdhary, A., Cornely, O. A., Denning, D. W., Groll, A. H., Izumikawa, K., et al. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.08.001 · Cited by 330 · cited 2×
“Recently, an international expert panel convened to deliberate the management of azole-resistant invasive aspergillosis, concluding that in culture-positive cases, in vitro susceptibility testing is highly indicated when antifungal therapy is intended [80].”
BackgroundSanguinetti, M., Posteraro, B., Fiori, B., Ranno, S., Torelli, R., & Fadda, G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.668-679.2005 · Cited by 319
Self-citationFerrari, S., Ischer, F., Calabrese, D., Posteraro, B., Sanguinetti, M., Fadda, G., Rohde, B., Bauser, C., Bader, O., & Sanglard, D. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000268 · Cited by 295
Self-citationHealey, K. R., Zhao, Y., Perez, W. B., Lockhart, S. R., Sobel, J. D., Farmakiotis, D., Kontoyiannis, D. P., Sanglard, D., Taj-Aldeen, S. J., Alexander, B. D., et al. (2016) · Nature Communications · doi:10.1038/ncomms11128 · Cited by 276
Antifungal Drugs: The Current Armamentarium and Development of New Agents
Robbins, N., Wright, G. D., & Cowen, L. E. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0002-2016 · Cited by 271 · cited 1×
“Paralleling the relatively recent introduction of new antifungal drug classes [7] and the discovery of novel agents [8] for the treatment of invasive fungal infections, the field of antifungal susceptibility testing (AFST) has progressed tremendously in the past several years [9].”
BackgroundAzole-Resistant Aspergillosis: Epidemiology, Molecular Mechanisms, and Treatment
Chowdhary, A., Sharma, C., & Meis, J. F. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix210 · Cited by 262
Espinel-Ingroff, A., Diekema, D. J., Fothergill, A., Johnson, E., Pelaez, T., Pfaller, M. A., Rinaldi, M. G., Canton, E., & Turnidge, J. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00536-10 · Cited by 240 · cited 1×
“versicolor) to aid in the early identification of clinical isolates with acquired resistance mechanisms [44,45].”
BackgroundEspinel-Ingroff, A., Arendrup, M. C., Pfaller, M. A., Bonfietti, L. X., Bustamante, B., Canton, E., Chryssanthou, E., Cuenca-Estrella, M., Dannaoui, E., Fothergill, A., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01519-13 · Cited by 216 · cited 1×
“Additionally, the interlaboratory variability in caspofungin MICs noted with Candida species may significantly hinder the use of both CLSI and EUCAST methods [24].”
Guinea, J., Peláez, T., Recio, S., Torres-Narbona, M., & Bouza, E. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01512-07 · Cited by 215 · cited 1×
“Using the strip’s full inhibition endpoint, the essential agreements with the EUCAST reference method (at ±1 and ±2 twofold dilutions) were 73–75% and 89–90% [49], which were better than previously found for the isavuconazole Etest (no longer available) when compared with the CLSI reference method [51].”
ResultPatel, R. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit247 · Cited by 204 · cited 1×
“In many European clinical microbiology laboratories such as ours, the advent of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) has drastically altered the routine diagnostic workflow [55,56].”
BackgroundCuenca-Estrella, M., Gomez-Lopez, A., Alastruey-Izquierdo, A., Bernal-Martinez, L., Cuesta, I., Buitrago, M. J., & Rodriguez-Tudela, J. L. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02316-09 · Cited by 173
Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi
McCarthy, M. W., Kontoyiannis, D. P., Cornely, O. A., Perfect, J. R., & Walsh, T. J. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix130 · Cited by 169 · cited 1×
“Paralleling the relatively recent introduction of new antifungal drug classes [7] and the discovery of novel agents [8] for the treatment of invasive fungal infections, the field of antifungal susceptibility testing (AFST) has progressed tremendously in the past several years [9].”
BackgroundPancholi, P., Carroll, K. C., Buchan, B. W., Chan, R. C., Dhiman, N., Ford, B., Granato, P. A., Harrington, A. T., Hernandez, D. R., Humphries, R. M., et al. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01329-17 · Cited by 168 · cited 1×
“Designed to identify common causes of bacteremia (~90 min) as well as perform antimicrobial susceptibility testing (~7 h) using positive blood cultures, the Food and Drug Administration (FDA)-cleared Accelerate PhenoTestTM Blood Culture kit represents an important breakthrough in the development of rapid phenotypic an…”
Marinach, C., Alanio, A., Palous, M., Kwasek, S., Fekkar, A., Brossas, J., Brun, S., Snounou, G., Hennequin, C., Sanglard, D., et al. (2009) · PROTEOMICS · doi:10.1002/pmic.200900152 · Cited by 159 · cited 1×
“In keeping with previous work that introduced the minimal profile change concentration (MPCC) as a new endpoint for AFST [66], our research group developed MALDI-TOF MS–based assays for testing the echinocandin susceptibility of fungal species.”
ResultChanging Epidemiology of Invasive Mold Infections in Patients Receiving Azole Prophylaxis
Lamoth, F., Chung, S. J., Damonti, L., & Alexander, B. D. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix130 · Cited by 155 · cited 1×
“Antifungal prophylaxis with antimol - ctive azole compounds (po aco azole or voriconazole) to reduce the incidence of invasive mold infections in high-risk patients may be associated with breakthrough inf ctions caused by rare multidrug-resistant molds [92].”
BackgroundSanguinetti, M., & Posteraro, B. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.01640-16 · Cited by 154 · cited 2×
“To date, MALDI-TOF MS analysis is suited for microbial isolates cultured from primary samples [60] or positive blood cultures [61], significantly reducing the turnaround time compared to biochemical [62] or nucleic acid–based techniques, such as DNA sequencing [63].”
BackgroundMethodSelf-citationArendrup, M. C., Meletiadis, J., Mouton, J. W., Guinea, J., Cuenca‐Estrella, M., Lagrou, K., Howard, S. J., Arendrup, M. C., Meletiadis, J., Howard, S. J., et al. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.01.017 · Cited by 145
Idelevich, E. A., Sparbier, K., Kostrzewa, M., & Becker, K. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.10.016 · Cited by 142 · cited 2×
“Further application of this or other game-changing technologies such as MALDI-TOF MS [90] to fungi would allow for similar gains in AFST performance, along with improvements of fungal diagnostic capability [91].”
BackgroundDe Carolis, E., Vella, A., Florio, A. R., Posteraro, P., Perlin, D. S., Sanguinetti, M., & Posteraro, B. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00224-12 · Cited by 140 · cited 2×
“[67] obtained mass spectra from fungal cells exposed to different caspofungin concentrations for 15 h, and then matched the “intermediate” mass spectra with each of the “extreme” mass spectra using composite correlation index (CCI) analysis.”
MethodResultSelf-citationChong, G. M., van der Beek, M. T., von dem Borne, P. A., Boelens, J., Steel, E., Kampinga, G. A., Span, L. F. R., Lagrou, K., Maertens, J. A., Dingemans, G. J. H., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw323 · Cited by 131 · cited 1×
“Molecular detection of resistance genes, especially when applied to primary clinical samples [85,86], may be a useful adjunct for fungal surveillance and disease diagnosis [46].”
MALDI-TOF mass spectrometry in the clinical mycology laboratory: identification of fungi and beyond
Posteraro, B., De Carolis, E., Vella, A., & Sanguinetti, M. (2013) · Expert Review of Proteomics · doi:10.1586/epr.13.8 · Cited by 128 · cited 3×
“However, this has occurred quickly for bacteria [58] but not so quickly for fungi [59].”
BackgroundSelf-citationVella, A., De Carolis, E., Vaccaro, L., Posteraro, P., Perlin, D. S., Kostrzewa, M., Posteraro, B., & Sanguinetti, M. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00903-13 · Cited by 124 · cited 1×
“[68] provided discrimination between susceptible and resistant isolates of C.”
BackgroundSelf-citationEspinel‐Ingroff, A., & Turnidge, J. D. (2016) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2016.04.001 · Cited by 123 · cited 1×
“However, in lieu of CBPs, establishing epidemiological cutoff values (ECVs) helped to distinguish wild-type (WT) isolates from those that may harbor an acquired resistance mechanism and are less likely to respond to a given antifungal agent (non-WT) [18].”
BackgroundXiao, M., Fan, X., Chen, S. C.-A., Wang, H., Sun, Z.-Y., Liao, K., Chen, S.-L., Yan, Y., Kang, M., Hu, Z.-D., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku460 · Cited by 122
Li, Y., Yang, X. H., & Zhao, W. (2017) · SLAS TECHNOLOGY · doi:10.1177/2472630317727519 · Cited by 114 · cited 1×
“Therefore, recent efforts have led to the development of innovative technologies that promise to shorten the turnaround time for phenotypic AFST results [88].”
BackgroundDudakova, A., Spiess, B., Tangwattanachuleeporn, M., Sasse, C., Buchheidt, D., Weig, M., Groß, U., & Bader, O. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00095-16 · Cited by 113 · cited 16×
“Arendrup et al. [49] evaluated the MIC Strip Isavuconazole test (Liofilchem, Roseto degli Abruzzi, Italy), the only commercially available isavuconazole susceptibility test, against EUCAST EDef 9.3 by using 40 WT and 39 CYP51A mutant isolates of A. fumigatus.”
BackgroundMethodInfluentialCharacterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin
Gardiner, R. E., Souteropoulos, P., Park, S., & Perlin, D. S. (2005) · Medical Mycology · doi:10.1080/13693780400029023 · Cited by 110
Posteraro, B., Efremov, L., Leoncini, E., Amore, R., Posteraro, P., Ricciardi, W., & Sanguinetti, M. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00802-15 · Cited by 97 · cited 1×
“To date, MALDI-TOF MS analysis is suited for microbial isolates cultured from primary samples [60] or positive blood cultures [61], significantly reducing the turnaround time compared to biochemical [62] or nucleic acid–based techniques, such as DNA sequencing [63].”
MethodSelf-citationEspinel-Ingroff, A., Chowdhary, A., Gonzalez, G. M., Lass-Flörl, C., Martin-Mazuelos, E., Meis, J., Peláez, T., Pfaller, M. A., & Turnidge, J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00636-13 · Cited by 97 · cited 1×
“versicolor) to aid in the early identification of clinical isolates with acquired resistance mechanisms [44,45].”
BackgroundDenning, D. W., Perlin, D. S., Muldoon, E. G., Colombo, A. L., Chakrabarti, A., Richardson, M. D., & Sorrell, T. C. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2302.152042 · Cited by 95 · cited 1×
“Further application of this or other game-changing technologies such as MALDI-TOF MS [90] to fungi would allow for similar gains in AFST performance, along with improvements of fungal diagnostic capability [91].”
Pfaller, M. A., Castanheira, M., Messer, S. A., Rhomberg, P. R., & Jones, R. N. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.03.004 · Cited by 92 · cited 1×
“In one large study published recently [27], good correlation was obtained between EUCAST (EDef 7.”
ResultMBT-ASTRA: A suitable tool for fast antibiotic susceptibility testing?
Sparbier, K., Schubert, S., & Kostrzewa, M. (2016) · Methods · doi:10.1016/j.ymeth.2016.01.008 · Cited by 85 · cited 1×
“While susceptibility testing methods are not directly applicable to primary samples [64], some recent studies have reported success with phenotype-centered (or semimolecular) MALDI-TOF MS methods for AFST [65].”
BackgroundFarmakiotis, D., & Kontoyiannis, D. P. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.05.019 · Cited by 83 · cited 1×
“The rise in echinocandin resistance, azole resistance, and cross-resistance to two or more antifungal classes (multidrug resistance) in pathogenic fungi [77] has involved species of Candida such as C.”
BackgroundFiori, B., D’Inzeo, T., Giaquinto, A., Menchinelli, G., Liotti, F. M., Maio, F. D., Angelis, G. D., Quaranta, G., Nagel, D., Tumbarello, M., et al. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.02590-15 · Cited by 79 · cited 1×
“To date, MALDI-TOF MS analysis is suited for microbial isolates cultured from primary samples [60] or positive blood cultures [61], significantly reducing the turnaround time compared to biochemical [62] or nucleic acid–based techniques, such as DNA sequencing [63].”
MethodSelf-citationAntifungal Resistance: An Emerging Reality and A Global Challenge
Kontoyiannis, D. P. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix179 · Cited by 76
Pfaller, M. A., Chaturvedi, V. P., Diekema, D. J., Ghannoum, M. A., Holliday, N. M., Killian, S. B., Knapp, C. C., Messer, S. A., Miskou, A., & Ramani, R. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.05.008 · Cited by 76 · cited 1×
“Nonetheless, they hold great value as indispensable comparators in evaluating performance studies of commercial methods [25,26], such as those discussed below.”
BackgroundPfaller, M. A., Messer, S. A., Diekema, D. J., Jones, R. N., & Castanheira, M. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.02481-13 · Cited by 74 · cited 1×
“While clinical microbiology laboratories should use micafungin and anidulafungin as surrogate markers to predict susceptibility or resistance to caspofungin [34,35], some authors have tried to establish ECVs using the SYO method [36,37].”
MethodPfaller, M. A., Espinel-Ingroff, A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02441-10 · Cited by 73 · cited 1×
“) between the two [16], CLSI and EUCAST have been proven to yield, upon completion of testing, comparable MIC data for all classes of antifungal agents [19,20].”
ResultPosteraro, B., Spanu, T., Fiori, B., De Maio, F., De Carolis, E., Giaquinto, A., Prete, V., De Angelis, G., Torelli, R., D'Inzeo, T., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00285-15 · Cited by 72 · cited 1×
“[29], susceptibility/WT rates to amphotericin B and flucytosine were over 97% in all yeast isolates (n = 1250, including Candida and non-Candida species).”
BackgroundSelf-citationJiménez-Ortigosa, C., Moore, C., Denning, D. W., & Perlin, D. S. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01277-17 · Cited by 72 · cited 1×
“Reduced susceptibility of Aspergillus fumigatus isolates to echinocandins in vitro can develop via FKS-dependent and FKS-independent mechanisms [40,41].”
BackgroundEspinel-Ingroff, A., Alvarez-Fernandez, M., Cantón, E., Carver, P. L., Chen, S. C.-A., Eschenauer, G., Getsinger, D. L., Gonzalez, G. M., Govender, N. P., Grancini, A., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01250-15 · Cited by 67 · cited 2×
“While clinical microbiology laboratories should use micafungin and anidulafungin as surrogate markers to predict susceptibility or resistance to caspofungin [34,35], some authors have tried to establish ECVs using the SYO method [36,37].”
BackgroundMethodSelf-citationEmergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance Mechanism.
Snelders, E., Lee, H., Kuijpers, J., Rijs, A., Varga, J., Samson, R., Mellado, E., Donders, A., Melchers, W., & Verweij, P. (2008) · SciVee · doi:10.4016/8254.01 · Cited by 67
Saraçlı, M. A., Fothergill, A. W., Sutton, D. A., & Wiederhold, N. P. (2015) · Medical Mycology · doi:10.1093/mmy/myv046 · Cited by 65
Vella, A., Carolis, E. D., Mello, E., Perlin, D. S., Sanglard, D., Sanguinetti, M., & Posteraro, B. (2017) · Scientific Reports · doi:10.1038/s41598-017-09329-4 · Cited by 64
Self-citationEschenauer, G. A., Nguyen, M. H., Shoham, S., Vazquez, J. A., Morris, A. J., Pasculle, W. A., Kubin, C. J., Klinker, K. P., Carver, P. L., Hanson, K. E., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02163-13 · Cited by 61 · cited 1×
“[28] underscored that adopting CLSI CBPs for caspofungin may overstate the rates at which isolates of C.”
BackgroundRueda, C., Puig-Asensio, M., Guinea, J., Almirante, B., Cuenca-Estrella, M., Zaragoza, O., Padilla, B., Muñoz, P., Guinea, J., Paño Pardo, J. R., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.09.016 · Cited by 58
Buil, J. B., van der Lee, H. A. L., Rijs, A. J. M. M., Zoll, J., Hovestadt, J. A. M. F., Melchers, W. J. G., & Verweij, P. E. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01250-17 · Cited by 57
Pfaller, M. A., Diekema, D. J., Jones, R. N., & Castanheira, M. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.00782-14 · Cited by 51 · cited 1×
“While clinical microbiology laboratories should use micafungin and anidulafungin as surrogate markers to predict susceptibility or resistance to caspofungin [34,35], some authors have tried to establish ECVs using the SYO method [36,37].”
MethodThe Slow March toward Rapid Phenotypic Antimicrobial Susceptibility Testing: Are We There Yet?
Doern, C. D. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01999-17 · Cited by 49 · cited 2×
“phenotypic antimicrobial susceptibility testing is [87].”
BackgroundCantón, E., Pemán, J., Hervás, D., Iñiguez, C., Navarro, D., Echeverría, J., Martínez-Alarcón, J., Fontanals, D., Gomila-Sard, B., Buendía, B., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.01730-12 · Cited by 48 · cited 1×
“While clinical microbiology laboratories should use micafungin and anidulafungin as surrogate markers to predict susceptibility or resistance to caspofungin [34,35], some authors have tried to establish ECVs using the SYO method [36,37].”
MethodANTIFUNGAL SUSCEPTIBILITY TESTING: CURRENT ROLE FROM THE CLINICAL LABORATORY PERSPECTIVE
Posteraro, B., Torelli, R., Carolis, E. D., Posteraro, P., & Sanguinetti, M. (2014) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2014.030 · Cited by 43 · cited 1×
“All of these achievements increased the likelihood that testing several organism–drug combinations (most notably Candida species and the azole antifungal agents) could usefully influence the selection of therapy, thus aiding clinicians in the management of difficult-to-treat fungal infections [17].”
BackgroundSelf-citationLockhart, S. R., Zimbeck, A. J., Baddley, J. W., Marr, K. A., Andes, D. R., Walsh, T. J., Kauffman, C. A., Kontoyiannis, D. P., Ito, J. I., Pappas, P. G., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00428-11 · Cited by 38 · cited 1×
“Despite being a rarity, echinocandin non-WT clinical isolates of Aspergillus species with MECs above the ECV were identified [39].”
Mass spectrometry applications in microbiology beyond microbe identification: progress and potential
Sanguinetti, M., & Posteraro, B. (2016) · Expert Review of Proteomics · doi:10.1080/14789450.2016.1231578 · Cited by 36 · cited 1×
“As a result, MALDI-TOF MS offers the chance to identify almost all microbial genera and species with unprecedented reliability, rapidity, and cost-effectiveness [57].”
BackgroundSelf-citationThe future of fungal susceptibility testing
Posteraro, B., & Sanguinetti, M. (2014) · Future Microbiology · doi:10.2217/fmb.14.55 · Cited by 34 · cited 4×
“European Committee on Antimicrobial Susceptibility Testing (EUCAST) reference methods currently in place [12–15], but also expansion of commercial and automated methods for AFST [16].”
MethodResultInfluentialSelf-citationNew approaches for antifungal susceptibility testing
Sanguinetti, M., & Posteraro, B. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.03.025 · Cited by 32 · cited 1×
“While susceptibility testing methods are not directly applicable to primary samples [64], some recent studies have reported success with phenotype-centered (or semimolecular) MALDI-TOF MS methods for AFST [65].”
BackgroundSelf-citationMello, E., Posteraro, B., Vella, A., Carolis, E. D., Torelli, R., D’Inzeo, T., Verweij, P. E., & Sanguinetti, M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00168-17 · Cited by 29 · cited 2×
“[48] performed visual readings of SYO MICs regardless of color changes, which were necessary because of prolonged incubation times (>24 h) of the SYO panels.”
BackgroundMethodSelf-citationKritikos, A., Neofytos, D., Khanna, N., Schreiber, P. W., Boggian, K., Bille, J., Schrenzel, J., Mühlethaler, K., Zbinden, R., Bruderer, T., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.05.012 · Cited by 28 · cited 1×
“[38] calculated echinocandin ECVs for C.”
Zhao, Y., Garnaud, C., Brenier‐Pinchart, M., Thiébaut, A., Saint‐Raymond, C., Camara, B., Hamidfar, R., Cognet, O., Maubon, D., Cornet, M., et al. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01164 · Cited by 27 · cited 1×
“Molecular detection of resistance genes, especially when applied to primary clinical samples [85,86], may be a useful adjunct for fungal surveillance and disease diagnosis [46].”
BackgroundAigner, M., Erbeznik, T., Gschwentner, M., & Lass‐Flörl, C. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00512-17 · Cited by 25 · cited 1×
“[54] showed that the levels of essential agreement with the EUCAST reference method were 97% and 92% for anidulafungin and micafungin.”
Siopi, M., Pournaras, S., & Meletiadis, J. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.00044-17 · Cited by 25 · cited 1×
“By the authors’ opinion [42], in an average clinical laboratory, a good compromise could be inoculating A.”
BackgroundGitman, M., McTaggart, L. R., Spinato, J., Poopalarajah, R., Lister, E., Husain, S., & Kus, J. V. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.00254-17 · Cited by 25 · cited 3×
“It is likely that some fungal isolates requiring additional time relates to the impossibility of their reaching enough growth and, consequently, level of expressed proteins to allow for correct classification by the MS-AFST assay [69,73].”
BackgroundMethodResultInfluentialArendrup, M. C., Verweij, P. E., & Nielsen, H. V. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01659-16 · Cited by 18 · cited 5×
“[49] evaluated the MIC Strip Isavuconazole test (Liofilchem, Roseto degli Abruzzi, Italy), the only commercially available isavuconazole susceptibility test, against EUCAST EDef 9.”
BackgroundMethodResultInfluentialIdelevich, E. A., Groß, U., Becker, K., & Bader, O. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.01.003 · Cited by 16 · cited 3×
“[50] evaluated Etest (bioMérieux) and MIC Test Strip (Liofilchem) for itraconazole, posaconazole, and voriconazole, and only MIC Test Strip for isavuconazole, against the EUCAST reference method by using clinical consecutive isolates (n = 24) and control strains (n = 15, with defined resistant or susceptible phenotype…”
BackgroundMethodThe Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus
Ostrosky-Zeichner, L. L., & Andes, D. R. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix239 · Cited by 14
Bougnoux, M., Dannaoui, É., Accoceberry, I., Angoulvant, A., Bailly, E., Botterel, F., Chevrier, S., Chouaki, T., Cornet, M., Dalle, F., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00630-16 · Cited by 12 · cited 1×
“[53] recently enrolled 16 French hospital centers to obtain 933 Candida isolates that were tested against micafungin.”
BackgroundWootton, M., MacGowan, A. P., & Howe, R. A. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw494 · Cited by 3 · cited 1×
“Apart from practical, reliable, and reproducible laboratory methods for AFST, there has been a considerable push toward methods able to correlate in vitro laboratory tests with clinical outcome and identify new, clinically important resistance mechanisms, as has been done for susceptibility testing of bacteria [10].”
Cited by
Houšť, J., Spížek, J., & Havlíček, V. (2020) · Metabolites · doi:10.3390/metabo10030106 · Cited by 254
Azole resistance mechanisms in Aspergillus: update and recent advances
Pérez-Cantero, A., López-Fernández, L., Guarro, J., & Capilla, J. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.09.011 · Cited by 172
Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy
Mercer, D. K., Torres, M. D. T., Duay, S. S., Lovie, E., Simpson, L., von Köckritz-Blickwede, M., de la Fuente-Nunez, C., O'Neil, D. A., & Angeles-Boza, A. M. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00326 · Cited by 132
“Antimicrobial susceptibility testing (AST) determines the concentration of an antimicrobial that inhibits microbial growth, for both microbicidal and microbiostatic agents (Brown et al., 2016; Sanguinetti and Posteraro, 2018; Humphries et al., 2019; van Belkum et al., 2019).”
BackgroundMethodNeofytos, D., García‐Vidal, C., Lamoth, F., Lichtenstern, C., Perrella, A., & Vehreschild, J. J. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-05958-3 · Cited by 69
“such as MALDI-TOF mass spectrometry assays [68], is of critical value for the treatment of such patients and”
Assress, H. A., Selvarajan, R., Nyoni, H. H., Mamba, B. B., & Msagati, T. A. M. (2021) · Reviews in Environmental Science and Bio/Technology · doi:10.1007/s11157-021-09594-w · Cited by 73
“…or yeasts, is comprised of two widely accepted standard methods, which are, the European Union Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standard Institute (CLSI), which both apply the broth macro/micro-dilution method (Sanguinetti and Posteraro 2018).”
Method
Metadata
- Authors
- Sanguinetti, M., & Posteraro, B.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- Corresponding author
- Sanguinetti, Maurizio
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2018-09-15
- Volume
- 4
- Issue
- 3
- Pages
- 110
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC6162686
- OpenAlex
- W2891394773
- Cited by
- 55
- References
- 87
- Citations by year
- 2026: 6 · 2025: 3 · 2024: 2 · 2023: 9 · 2022: 9 · 2021: 12 · 2020: 6 · 2019: 5 · 2018: 1
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Keywords
- antifungal susceptibility testing, invasive fungal infections, Candida, Aspergillus, MALDI-TOF mass spectrometry, Sensititre YeastOne, E-test, antifungal resistance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.